Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Vilobelimab (Primary)
- Indications Pyoderma gangrenosum
- Focus Adverse reactions; Proof of concept
- Acronyms OPTIMA
- Sponsors InflaRx
Most Recent Events
- 07 Mar 2025 According to an InflaRx media release, the data from this study being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting being held March 7 - 11, in Orlando, FL.
- 07 Mar 2025 Results published in the InflaRx Media Release
- 28 Feb 2025 According to an InflaRx media release, company to present data from this study in 3 ePoster presentations at the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.